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Abstract
Oncostatin M (OSM) is an interleukin-6-like inflammatory cytokine reported to play a role in a
number of pathological processes including cancer. Full-length OSM is expressed as a 26 kDa
protein that can be proteolytically processed into 24 kDa and 22 kDa forms via removal of Cterminal peptides. In this study, we examined both the ability of OSM to bind to the extracellular
matrix (ECM) and the activity of immobilized OSM on human breast carcinoma cells. OSM was
observed to bind to ECM proteins collagen types I and XI, laminin, and fibronectin in a pHdependent fashion, suggesting a role for electrostatic bonds that involves charged amino acids
of both the ECM and OSM. The C-terminal extensions of 24 kDa and 26 kDa OSM, which
contains six and thirteen basic amino acids, respectively, enhanced electrostatic binding to ECM
at pH 6.5-7.5 when compared to 22 kDa OSM. The highest levels of OSM binding to ECM,
though, were observed at acidic pH 5.5, where all forms of OSM bound to ECM proteins to a
similar extent. This indicates additional electrostatic binding properties independent of the OSM
C-terminal extensions. The reducing agent dithiothreitol also inhibited the binding of OSM to
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ECM suggesting a role for disulfide bonds in OSM immobilization. OSM immobilized to ECM
was protected from cleavage by tumor-associated proteases and maintained activity following
incubation at acidic pH for extended periods of time. Importantly, immobilized OSM remained
biologically active and was able to induce and sustain the phosphorylation of STAT3 in T47D
and ZR-75-1 human breast cancer cells over prolonged periods, as well as increase levels of
STAT1 and STAT3 protein expression. Immobilized OSM also induced epithelial-mesenchymal
transition-associated morphological changes in T47D cells. Taken together, these data indicate
that OSM binds to ECM in a bioactive state that may have important implications for the
development of chronic inflammation and tumor metastasis.
Keywords: cytokines, extracellular matrix, collagens, cancer, metastasis, inflammation, Col11a1, oncostatin M,
OSM, electrostatic binding, arthritis
Abbreviations
OSM, oncostatin M; IL-6, interleukin-6; LIF, leukemia inhibitory factor; PBS, phosphate-buffered saline; TBS, Trisbuffered saline; TTBS, Tween-20/Tris-buffered saline; DTT, dithiothreitol; TX, Triton X-100; NC4, Col-I, collagen
type I; Col-XI, collagen type XI; Lam, laminin; Fn, fibronectin; ECM, extracellular matrix; EMT, epithelial-tomesenchymal transition; SPR, surface plasmon resonance; MWs, molecular weights; TGF-ȕWUDQVIRUPLQJ JURZWK
factor-ȕ+*)KHSDWRF\WHJURZWKIDFWRU6)0VHUXPIUHHPHGLXP&0WXPRUFRQGLWLRQHGPHGLDN'DNLORGDOWRQV
FBS, fetal bovine serum.

1. Introduction
Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) cytokine family, which signals cancer cells primarily
through STAT3 to promote a metastatic phenotype via effects on tumor cell proliferation, attachment to substratum,
migration, invasion, metastasis and the epithelial-to-mesenchymal transition (EMT) (1-8). OSM is expressed as a 26
kDa MW protein (full-length) that can be proteolytically processed into 24 kDa OSM via proteolytic cleavage of
eighteen C-terminal amino acids, as well as a 22 kDa form via removal of an additional thirteen C-terminal amino
acids by a trypsin-like protease (9). OSM with MWs of 22 kDa and 26 kDa are reported in rat testis that differ in MW
due to OSM glycosylation, and are suggested to have different functions in spermatogenesis (10). OSM is reported to
induce acute inflammation upon subcutaneous injection into mice (11) and can regulate inflammation via the induction
of both proteases and protease inhibitors (12, 13). OSM regulates proteolysis and extracellular matrix (ECM) turnover
via the induction of cysteine and aspartic proteases, as well as metalloproteinases (3, 14, 15). In addition to its role in
the inflammatory process associated with tumor progression, OSM drives other pathological conditions involving
chronic inflammation including arthritis (16-20), Alzheimer’s disease (21-23) and atherosclerosis (24). The
importance of inflammation in cancer is well established, since patients suffering from chronic inflammatory
conditions such as pancreatitis, inflammatory bowel disease, prostatitis, and chronic obstructive pulmonary disease
are more prone to develop cancer in affected tissues (25-28). In addition, a link between arthritis-induced inflammation
and secondary metastasis associated with breast cancer has recently been established (29, 30).
IL-6 family members, including OSM, and the JAK/STAT pathway have recently emerged as key players in cancerassociated inflammation (4, 27, 31-34). Most inflammatory signals affect tumor progression by activating STAT3 and
NF-ț%(32). OSM signaling through STAT3 is involved in the regulation of both systemic and local inflammatory
responses in a variety of tumors (33, 35), shaping the tissue microenvironment into one that is pro-tumorigenic and
inflammatory (36). Interestingly, unphosphorylated STAT3 is also reported to activate cell signaling associated with
inflammation (37, 38).
The ECM is a complex and dynamic material that provides structural support for cells (39, 40). The ECM also
functions in ways beyond structural support and is important in phenomena as diverse as developmental patterning,
stem cell niches, genetic diseases, and cancer (39, 40). ECM proteins regulate paracrine, autocrine, juxtacrine, and
matricrine signaling in cells (41) and numerous growth factors and cytokines promote expression of ECM proteins
(39, 40). OSM is reported to enhance fibronectin expression in T47D breast tumor cells, as well as regulate ECM
deposition in MCF-7 breast tumor cells (8). OSM also stimulates excessive ECM production and accumulation in
connective tissue disease in vivo (42), and in vitro in human dermal fibroblasts, pancreatic stellate cells, and lung
fibroblasts (42-46). Additionally, the ECM acts as a reservoir of biologically active molecules and as a storage site
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for growth factors, cytokines, and proteases (39, 47, 48), regulating their distribution, activation, and presentation to
cells (41). Recently, the invasiveness and malignant properties of ovarian tumors were reported to be enhanced by
collagen type XI expression (49).
Many interactions between ECM proteins and cytokines are highly specific. Variations in localization of specific ECM
protein isoforms, the extent of ECM protein glycosylation and the type of glycosaminoglycan groups present on
proteoglycan molecules all work together to determine the distribution of specific cytokines within the ECM,
providing an additional layer of regulation for cytokine activity (41). As solid phase ligands, ECM proteins integrate
complex, multivalent signals to cells in a spatially and temporally patterned fashion (40). The ability of particular
cytokines to bind and be immobilized by ECM proteins can accentuate their action by: 1) promoting the accumulation
of cytokines in a particular microenvironment and to increase their encounter with target cells; 2) activating cytokines
by inducing conformational changes in the bound cytokine; 3) promoting conformation-dependent association of
cytokines and their cell-surface receptors, as well as the assembly of the appropriate protein complexes necessary to
elicit signal transduction; and 4) protecting cytokines from both physiological and chemical degradation (41).
Limited studies have previously indicated an interaction between OSM and specific ECM molecules including
collagen type I (50) and fibromodulin (51). OSM possesses charged clusters of basic amino acids within its C-terminal
region, which are proposed to enhance binding to ECM components (51). In addition, OSM contains five cysteine
residues, three of which are localized to its surface and are reported to mediate immobilization to gold nano-clusters
(52). In this study, the interactions between OSM and the ECM molecules collagen types I and XI, fibronectin, and
laminin were examined, and their binding properties investigated for potential involvement in chronic inflammation
and tumor metastasis. Our data indicate that OSM binds to ECM proteins in a bioactive conformation, which may
play an important role in the development of an inflammatory, pro-tumorigenic environment.
2. Experimental Procedures
2.1 Materials.
The following reagents were obtained from commercial sources: full-length 26 kDa (227 amino acids) OSM
(Invitrogen, Life Technologies, Grand Island, NY); 22 kDa (196 amino acids) OSM and neutralizing antibody (R&D
Systems, Minneapolis, MN); 24 kDa (209 amino acids) OSM (Peprotech, Oak Park, CA); antibody to OSM employed
in immunoblots (Santa Cruz Biotechnologies, CA); collagen type I, laminin and fibronectin, ECM-coated 6-well plates
(Collaborative Biomedical Products, Bedford, MA); protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO);
Cleland’s reagent (DTT) (Sigma, St. Louis, MS) and RPMI-1640 growth medium (Hyclone, Logan, UT).
5HFRPELQDQWFROODJHQĮ ;, IUDJPHQWZDVV\QWKHVL]HGLQRXUODERUDWRU\DVSUHYLRXVO\UHSRUWHG(53).
2.2 Co-culture experiments.
Neutrophils were isolated from whole blood employing PolymorphprepTM solution (Sigma, St. Louis, MO).
Neutrophils were added to tumor cells at a ratio of 10:1 and cultured in RPMI, 10% FBS, with penicillin and
streptomycin.
2.3 Immunohistochemistry.
Formalin fixed, paraffin-embedded tumor specimens were obtained from the archives of the Department of Veterans
Affairs Medical Center, Boise ID. Following deparaffinization in xylenes and rehydration in a graded ethanol series,
the sections were washed with 0.1 M Tris-HCl, 0.1 M NaCl, pH 7.5 and incubated with hydrogen peroxide in methanol
to neutralize endogenous peroxidase activity. Sections were incubated with proteinase K (Sigma, St. Louis, MO),
followed by microwaving for 2.5 min in Antigen Unmasking Solution (Vector Labs, Burlingame, CA). Slides were
then washed and incubated in 20 % FBS (Sigma, St. Louis MO) to reduce non-specific binding. Two distinct OSMdirected monoclonal antibodies (a kind gift from Dr. Phil Wallace, Bristol-Myer Squibb Pharmaceutical Research
Institute, Seattle, WA) were previously characterized (54, 55). This OSM antibody cocktail was added (20.0 μg/mL
in 0.05 % FBS) and slides were incubated overnight at 4ºC. The tumor sections were incubated with biotinylated antirabbit/anti-mouse secondary antibody (Dako Corp., Carpinterio, CA) for 20 min, followed by incubation with
streptavidin/horseradish peroxidase (Dako Corp.) for 20 min. The slides were then incubated with substrate (3-amino-
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9-ethylcarbazole in N,N-dimethylformamide (Dako, Corp.) for up to 10 min and counterstained with hematoxylin
(Buffalo Supply, Louisville, CO) for 1 min. After counterstaining, the tissue sections were prepared with Aqua-Mount
(Lerner Laboratories, Pittsburg, PA).
2.4 Binding of OSM to ECM components in vitro.
Tissue culture plates were coated with ECM preparations (100 μl of 0.2 mg/mL in PBS, room temp) for 60 min.
Excess ECM solution was then decanted and plates were air dried in a cell culture hood and stored at 4ºC. Wells were
rinsed with serum-free RPMI-1640 culture media (SFM) for 15 min and then incubated for 15 min with SFM at the
particular pH to be tested. Fifty-seventy nanograms of 22 kDa, 24 kDa or 26 kDa OSM was added to each well in 0.5
mL SFM, incubated for 3 h at 37ºC, pH 5.5, 6.5 or 7.5, and then washed 4 times for 10 minutes with 1 mL of culture
medium of the corresponding pH. SFM was employed in the binding experiments to examine the binding of OSM in
the ionic milieu associated with a physiological environment and to make this model relevant to tissue culture. After
washing the samples, 80 μl of boiling lysis solution (1.0 % SDS; 1 mM sodium vanadate and 10 mM Tris-HCl, pH
7.4) was applied to recover the OSM bound to ECM, followed by a 10 μl lysis solution rinse that was pooled with the
corresponding samples. Experiments were also conducted with extended washing steps up to 48 h to validate the
properties of immobilized OSM.
2.5 Binding analysis by surface plasmon resonance.
6XUIDFHSODVPRQUHVRQDQFH 635 PHDVXUHPHQWVZHUHSHUIRUPHGDWÛ&XVing a Reichert SR7000 instrument in-line
with a Surveyor LC pump and autosampler. OSM was immobilized to the surface of a PEG-10% carboxyl mixed selfassembled monolayer surface on gold sensor chip. Briefly, the chip surface was activated with a 0.4 mM N-ethyl-N(3-diethylaminopropyl) carbodiimide and 0.1 mM N-hydroxysuccinimide in 0.5 M MES buffer followed by the
injection of OSM at a concentration of 20 μg/ml in 10 mM sodium acetate buffer (pH 4.5). Unreacted Nhydroxysuccinimide ester groups were blocked with 1 M ethanolamine hydrochloride. ECM samples were prepared
in phosphate buffered saline (PBS) with 0.05% Tween-20 (pH 7.4), which was filtered through a 0.45 μm filter prior
to use. All samples consisted of 100 μl injections at a flow rate of 50 μl/min. After an association phase, dissociation
phase was initiated and monitored in running buffer without the presence of ECM analyte for 180 s. The surface was
regenerated with a 15 s injection of 250 mM NaCl in PBS. The association and dissociation phases were followed in
real-time by monitoring changes in signal expressed in refractive index units and the data displayed as refractive index
units versus time. Each concentration was run in triplicate for each analyte injected across the chip surfaces. Blank
samples were included in the experiment to control for background signal and subtracted during post-processing. Data
were fit to an association-then-dissociation kinetic binding model with GraphPad Prism version 5.0 d for Mac OS X
(GraphPad Software, La Jolla California USA, www.graphpad.com).
2.6 Immunoblot procedure.
Nitrocellulose was incubated in Superblock (Pierce, Thermo Fisher Scientific Inc., Rockford, IL) for 1 h, rinsed in
Tris-buffered saline with 0.05 % Tween-20 (TTBS) and incubated with primary antibody (1 μg/ml) overnight at 5ºC.
Blots were then washed with TTBS 3X followed by incubation with secondary antibody (1/3000) in TTBS for 1-1.5
h at room temperature. Blots were then washed 3X in TTBS and developed using ECL substrates (Pierce, Thermo
Fisher Scientific Inc., Rockford, IL).
2.7 Assessment of the bioactivity of ECM-bound and soluble OSM.
Bioactivity was assessed by adding tumor cells to culture plates containing OSM immobilized to ECM proteins. Prior
to the addition of tumor cells to ECM-bound OSM, one set of sample wells was treated with an OSM neutralizing
antibody directed against the receptor binding site of OSM (3 μg/ml) for 60 min. T47D or ZR-75-1 tumor cells were
plated in each well to approximately 75% confluence. Following incubations ranging from 2 h-5 days, tumor cell
samples with ECM-bound OSM were harvested with 100 μl of boiling lysis buffer and 3 μl of protease inhibitor
cocktail. Phospho-STAT3, STAT3 and STAT1 levels induced by immobilized OSM bound were assessed by
immunoblot and compared to the levels of OSM in wells that received neutralizing antibody, or control wells that did
not receive OSM.
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2.8 Protein array analysis of STAT1 and STAT3 expression.
ZR-75-1 cells were treated with OSM (20 ng/ml) for 48 h in confluent 75 cm2 culture flasks. Control- and OSMtreated breast tumor cells were then harvested with boiling lysis solution. Samples were submitted to BD Transduction
Labs for a BD Powerblot protein array analysis that included STAT1 and STAT3 proteins. Samples were processed
in duplicate by immunoblot analysis and quantitated by densitometry via the ratio of protein expression in OSM treated
samples versus control samples.
2.9 OSM Circle assay.
To study the effects of immobilized OSM on the properties and morphology of breast tumor cells, as well as study the
properties of OSM bound to ECM for prolonged incubation periods the ‘OSM circle’ assay was developed. OSM (50
ng: 100μg/ml stock) was mixed 1:2 (vol/vol) with complete RPMI and spotted (20 μl total) into the middle of a culture
well (OSM circle), incubated for 3h (37ºC, pH7.5) and then washed extensively to remove any OSM not bound to
substratum. T47D cells were either added after washing, or following an extended incubation of immobilized OSM
(up to 8 days) in complete RPMI with additional washing. The effect of immobilized OSM on the morphology of cells
within the ‘OSM circle’ was compared to cells outside the ‘OSM circle’ for up to 28 days utilizing phase-contrast
microscopy.
2.10 Electrostatic and disulfide bond-dependent interaction between OSM and ECM.
Truncated 22 kDa OSM (196 amino acids), 24 kDa OSM (209 amino acids), and 26 kDa full-length OSM (227 amino
acids) were bound to ECM (as described above) at pH 7.5, 6.5 and 5.5 for 2-3 h at 37ºC; harvested with boiling lysis
buffer (100 Pl) and then assessed by immunoblot. To study the role of disulfide bonds in OSM immobilization to
ECM, 1 mM Cleland’s reagent (dithiothreitol; DTT) was included in the binding assay.
2.11 The proteolytic processing of soluble versus immobilized OSM by tumor secreted proteases.
Full-length 26 kDa OSM was bound to ECM and extensively washed. Tumor conditioned media (CM) was generated
by incubating a confluent 75 cm2 culture flask of breast tumor cells in 10 mL of SFM for 24h. The CM was collected
and clarified by brief centrifugation. In the immobilized OSM processing assay 0.5 ml of CM or SFM was added to
wells and following 24h incubation (room temp, pH7.5), 70 μl of boiling lysis buffer was added along with 3 μl of
protease inhibitor cocktail. OSM band intensities were examined by immunoblot analysis. The processing of
immobilized OSM was also compared to the processing of soluble OSM. The soluble OSM processing assay consisted
of 50 ng of 26 kDa OSM in 35 μl of CM or SFM (room temp, pH7.5). The assay was stopped after 24h by the addition
of SDS-PAGE sample buffer. Samples were examined via immunoblot.
3. Results
3.1 OSM is associated with ECM in an in vitro co-culture model and in human tumor tissue.
Neutrophils are a primary source of OSM within a tumor (6, 17, 56). We have previously established that, while both
neutrophils and breast cancer cells alone express relatively low levels of OSM, 24-hour co-culture of these two cell
types results in tumor cell-promoted neutrophil OSM expression and secretion (6). In the current study, OSM
expression was observed within human neutrophils after co-culturing with MDA-MB-231 breast cancer cells for 24
hours (Fig. 1A). Interestingly, after co-culture for 48 hours, OSM was detected in the neutrophils, as well as in the
pericellular matrix surrounding the breast cancer cells (Fig. 1B). This experiment indicated that co-culture of
neutrophils and tumor cells resulted in a reservoir of OSM associated with the ECM. Furthermore, OSM was detected
within the ECM in several human tumors of different histological origin, representing a general phenomenon that is
not restricted to breast cancer cells alone. A colorectal tumor with a high number of infiltrating neutrophils expressing
OSM is shown in Figure 1C. A high magnification image (100X) indicated that OSM was also associated with the
tumor ECM (Fig. 1D). Association of OSM with tumor ECM was also observed in an ovarian carcinoma, as depicted
in serial sections of the same tumor (Fig. 1E and F). OSM was also localized around an orifice not associated with
endothelial cells (arrow in Fig. 1F). This type of tumor structure may be produced by neutrophils creating a neutrophil
canal (57), which can be observed in an ovarian carcinoma containing OSM-expressing neutrophils (Fig. 1G).
Together, these results demonstrated that OSM is associated with the ECM of tumor cells both in vitro and in vivo.
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3.2 OSM binds electrostatically to ECM via charged amino acids in OSM and ECM proteins with a further potential
role for disulfide bonds.
Having established a physiological relevancy for ECM-immobilized OSM, we next examined the ability of full-length
26 kDa OSM (227 amino acids) versus 22 kDa C-terminal truncated OSM (196 amino acids) to bind to the ECM
molecules collagen types I and XI, laminin and fibronectin. OSM binding to ECM at physiological pH (7.5) was
compared to more acidic pH, including pH 6.5 and pH 5.5, which is characteristic of an inflammatory
microenvironment (58, 59). A pH dependent binding of OSM to each ECM protein was observed, which suggested
an electrostatic binding mechanism (Fig. 2A). Full length OSM (26 kDa) was observed to bind to ECM proteins to a
greater extent than 22 kDa OSM at pH 7.5 and 6.5, as assessed by band intensities in the immunoblot (Fig. 2A). The
most significant difference between the binding of 26 kDa OSM versus 22 kDa OSM to ECM at pH 6.5 and 7.5 was
observed for recombinant collagen type XI at neutral pH, where full-length OSM readily bound to collagen type XI,
whereas very little 22 kDa OSM bound (Fig. 2A). This experiment indicated that the C-terminal extension of fulllength OSM enhanced binding to ECM at physiological pH. At acidic pH 5.5, full-length and 22 kDa OSM bound
equally well to ECM proteins except for collagen type XI (Fig. 2A). The highest overall levels of OSM binding to
ECM were also observed at acidic pH, which was apparent from the intensities of the OSM bands (Fig. 2A). These
observations indicated electrostatic OSM binding properties at pH 5.5 independent of the C-terminal extension of full
length OSM.
A role for pairs or doublets of basic amino acids in OSM binding to ECM molecules such as fibromodulin and
osteoadherin has been reported previously (51). Full-length OSM has five basic amino acid doublets clustered in its
C-terminus compared to one pair for 22 kDa OSM (Table 1). To further examine the nature of OSM binding to ECM,
the binding of 26 kDa OSM was compared to the binding of 24 kDa OSM. Six of the thirteen amino acids in the Cterminal extension of 24 kDa OSM are charged 197-HSPHQALRKGVRR-209 (Table 1). 24 kDa OSM was observed
to bind collagen types I and XI, fibronectin, and laminin to a greater extent than 26 kDa OSM at pH 6.5 and 7.5 (Fig.
2B). At pH 5.5, similar levels of OSM binding to ECM proteins were observed. A pH dependent binding was apparent
for all ECM proteins except for 24 kDa OSM binding to collagen type XI, which tended to bind at similar high levels.
This set of OSM binding experiments demonstrated that OSM MW variants were associated with different ECM
binding properties that were regulated by pH, which was indicative of electrostatic binding. These experiments also
indicated that particular basic amino acids, or doublets, as well the position and accessibility of these basic residues
to ECM binding sites may be important determinants of OSM binding to ECM. In addition, at pH 5.5 changes in the
properties of OSM binding sites, as well as ECM binding sites may affect OSM binding to ECM.
Since OSM contains three cysteine residues at its surface (60), experiments were conducted to determine whether
disulfide bonds were also involved in the immobilization of OSM to ECM. Full-length 26 kDa and 24 kDa OSM
were incubated with the disulfide bond-reducing reagent dithiothreitol (DTT; Cleland’s reagent; 1 mM) and the effects
of DTT on OSM binding to ECM were then assessed by immunoblot. The binding properties of 22 kDa OSM were
not examined due to the low levels of ECM binding observed in Figure 2A. In these experiments, DTT inhibited or
reduced the binding of OSM to collagens type I and XI, laminin and fibronectin at pHs 7.5, 6.5 and 5.5 (Fig. 2B and
C), suggesting a change in OSM conformation due to DTT dissociation of disulfide bonds. The effect of DTT appeared
to be greater on the binding of 26 kDa versus 24 kDa OSM for each ECM protein examined. This experiment
suggested a potential role for disulfide bonds in OSM immobilization to ECM, involving cysteine residues in OSM.
To examine OSM binding to ECM from a different perspective, OSM molecules were immobilized to a PEG-sensor
chip and the binding of ECM was examined (pH 7.4) by surface plasmon resonance measurements (Fig. 3, Table 2).
Binding was observed between OSM and collagen type XI, fibronectin, and laminin.
3.3 OSM bound to ECM is biologically active.
The next set of experiments was designed to determine whether immobilized OSM was bioactive and able to initiate
OSM signaling in breast tumor cells (Fig. 4). The first experiment compared the activities of full-length versus 22
kDa OSM in a traditional time-course assay employing soluble OSM (25 ng/ml) to examine the phosphorylation of
the OSM signaling protein STAT3. Addition of soluble 26 kDa OSM or 22 kDa OSM to T47D human breast cancer
cells resulted in the phosphorylation of STAT3 apparent at 15 minutes; that reached a maximum by 30 minutes and
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then decreased by 60 minutes, as assessed by immunoblot analysis (Fig. 4A). Both 26 kDa and 22 kDa OSM were
able to activate OSM signaling via pSTAT3 to a similar extent, which indicated similar activities for the two OSM
forms.
In the next set of experiments, we determined whether OSM immobilized to ECM was biologically active. Full-length
26 kDa and 22 kDa OSM were bound to ECM components for 3 hours in serum-free media (pH 7.4, 37 ºC), excess
OSM was removed, and T47D or ZR-75-1 human breast cancer cells were added and cultured for 2 or 24 hours,
respectively. Two hours was selected as the early time-point, because this was the minimum time required for T47D
cells to adhere to substratum and begin to flatten to a control-morphology. Both 26 kDa and 22 kDa OSM immobilized
to collagen type XI, laminin, fibronectin, or collagen type I induced pSTAT3 in T47D (Fig. 4B) and ZR-75-1 (Fig.
4C) cells, demonstrating that OSM bound to these ECM proteins in a bioactive conformation. An OSM neutralizing
antibody inhibited the induction of pSTAT3 by full-length OSM and 22 kDa OSM in each cell line (Fig. 4B and C).
This indicated that induced pSTAT3 was due to OSM receptor (OSMR) signaling and also demonstrated that the
OSM-ECM binding site was distinct from the OSMR binding site, which was recognized by the neutralizing antibody.
In Figure 2A, 22 kDa OSM was observed to bind to ECM proteins, particularly collagen-type XI at low levels (pH
6.5-7.5) compared to 26 kDa OSM, as indicated by the low intensity OSM bands assessed by immunoblot. In contrast,
in Figure 4, immobilized 22 kDa OSM was observed to generate pSTAT3 bands similar in intensity to 26 kDa OSM.
This discrepancy was determined to result from the threshold of detection for the two methods of analysis (Sup. Fig.1).
Two to three nanograms of OSM protein were required to detect immobilized OSM in immunoblots, which was
dependent on the sensitivity of the OSM antibody. Faint intensity OSM bands observed in immunoblots from ECM
binding experiments, though, were still associated with enough immobilized OSM to generate a strong pSTAT3 band
in an OSM activity assay (Sup. Fig.1). This was particularly true for pSTAT3 assessed at 24 h or longer.
We also demonstrated that 22 kDa and 26 kDa OSM bound to collagens type I and XI to a greater extent than IL-6 or
LIF based on pSTAT3 expression (Sup. Fig. 2). IL-6, which contains seven charged acid amino residues but no basic
amino acid doublets in its C-terminus (Table 1), did not induce pSTAT3 in T47D cells following incubation with
collagens type I and XI. This indicated that IL-6 did not bind to ECM in a bioactive conformation (Sup. Fig. 2). IL-6
does contain one doublet of charged amino acids in its C-terminus that consists of one basic and one acidic residue
(Table 1). LIF is associated with eight charged amino acids in its C-terminus, including a cluster of lysines, K-158,
K-159 and K-160, as well as lysines at positions K-168 and K-170 (Table 1). LIF was observed to bind to collagens
type I and XI as indicated by pSTAT3 bands, but not as well as 22 kDa or 26 kDa OSM (Sup. Fig. 2). This experiment
supported a role for pairs or clusters of basic amino acids in mediating IL-6-like cytokine binding to ECM.
3.4 OSM immobilized to ECM induces a prolonged pSTAT3 response and enhances STAT1 and STAT3 protein
expression.
STAT proteins, particularly STAT3 have been described as key mediators of cancer-associated inflammation (31-36,
61) and are associated with OSM signaling. Therefore, we assessed the effects of immobilized OSM on the expression
of STAT3 and STAT1 and phosphorylation of STAT3 (Tyr-705) in T47D breast cancer cells after extended incubation
periods. We hypothesized that the prolonged presence of OSM, as well as STAT proteins in a particular
microenvironment were necessary to mediate cycles of inflammatory events and tumor progression. OSM
immobilized to collagen type XI induced a sustained expression of pSTAT3 in T47D cells that reached a maximum
at 1 to 3 days and remained elevated over 5 days (Fig. 5A). This experiment indicated that immobilized OSM could
mediate long-term biological effects in tumor cells. The data in Figures 4A and 5A also suggested a bi-phasic pSTAT3
response that increased at 15 to 45 minutes, decreased by 60 minutes to 3 hours, and then increased again from 1 to 3
days. Interestingly, immobilized OSM also enhanced unphosphorylated STAT3 expression that remained elevated
after 5 days (Fig. 5A), as well as unphosphorylated STAT1 expression that remained elevated after 4 days (Fig. 5B).
These data were supported by protein array analysis of ZR-75-1 breast cancer cells, where cells treated with soluble
OSM for 2 days resulted in a greater than 2-fold induction levels of both STAT3 and STAT1 (Fig. 5C).
Immobilized OSM could be recovered and analyzed by immunoblot from the T47D cell lysates for the 5-day culture
period (Fig. 5A and B). This indicated that immobilized OSM maintained bioactivity and was able to bind to cellular
receptors and that detached, unbound OSM was not necessary to elicit OSM signaling. A decrease in the recovered
OSM band was also apparent over time (Fig. 5A and B). OSM bound to ECM via low affinity binding sites may
detach at early time points (compare heavy band at 2 hours that decreases at 1 day) versus higher affinity binding sites
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that maintained prolonged binding of OSM to substratum. In summary, the enhanced and sustained expression of
pSTAT3 and STAT3, as well as STAT1 protein levels in breast cancer cells treated with immobilized OSM is a novel
observation and suggests an important role for OSM in STAT-mediated inflammation and tumor progression.
3.5 OSM bound to ECM induces morphological changes in breast tumor cells.
We also assessed the activity of immobilized OSM by examining morphological changes in T47D breast cancer cells
following interaction with immobilized OSM. For this analysis, we developed the OSM ‘circle assay’ (Fig. 6A), which
confirmed that immobilized OSM was bioactive and able to interact with cellular receptors and that detached, soluble
OSM was not responsible for the biological effects being observed. The differences in light reflection/refraction in
T47D breast tumor cells within the ‘OSM circle’ undergoing EMT associated morphological changes (3) were
compared to the properties of control cells outside the ‘OSM circle’. In addition, gross morphological changes in
tumor cells within the ‘OSM circle’ were compared to the morphology of cells outside the ‘OSM circle’ to assess
biological changes in cells induced by immobilized OSM and to determine whether OSM effects remained associated
with cells inside the circle over prolonged incubation periods. In these experiments, 26 kDa OSM (50 ng: 100 μg/ml
stock) was spotted on an ECM coated dish for 3 hours (pH 7.5, 37 ºC), rinsed and incubated for 5 days. After additional
washes, T47D cells were added and incubated for 8 days (Fig. 6B-E). OSM immobilized to laminin inside the ‘OSM
circle’ induced morphological changes, as well as the detachment of T47D cells (Fig. 6B and D). T47D cells outside
the ‘OSM circle’ (Fig 6C and E) remained attached to laminin and maintained a control morphology.
Plastic was also employed as a substratum due to concerns that ECM proteins might slowly detach from substratum
after prolonged incubation with tumor cells. In this experiment, 26 kDa OSM was immobilized in a circle on plastic
tissue culture wells (3-hour binding, 37ºC, pH 7.5). T47D cells were then added and cultured for 28 days, with fresh
media added every 5 days (Figure 6F-I). After the prolonged incubation, T47D cells associated within the ‘OSM
circle’ (Fig. 6F and 6H) were associated with EMT-like morphological differences compared to cells just outside the
‘OSM circle’ (Fig. 6G and 6I), which maintained control morphology. Cells inside the ‘OSM circle’ had a larger cell
volume than those outside the circle and were associated with a more stellate morphology with arm-like processes
protruding from the cells. Cells inside the ‘OSM circle’ undergoing morphological changes (Fig 6F and 6H) also
appeared much brighter under a phase/contrast microscope than cells outside the ‘OSM circle’, which maintained a
darker control morphology and refracted/reflected light differently (Fig. 6G and 6I). It should also be noted that the
number of cells inside the OSM circle was less than that of cells outside the circle, which were hyper-confluent. The
decrease in cell number inside the ‘OSM circle’ resulted from OSM-induced cell detachment from substratum, as well
as growth arrest (3). OSM bound to other substratum was also observed to be bioactive in the ‘circle assay’ and further
demonstrated that OSM- mediated morphological effects were apparent only in cells within the ‘OSM circle’ (Sup.
Fig. 3). In summary, these experiments provided strong evidence for the ability of OSM to bind to substratum in a
bioactive conformation that was maintained during a prolonged incubation period and demonstrated that immobilized
OSM was able to bind to cellular OSM receptors.
3.6 OSM bound to ECM is protected from proteolysis and maintains stability in an acidic environment.
We next examined the effect of extracellular proteases associated with tumor-conditioned media (CM) on the
proteolysis of immobilized versus soluble OSM. Overnight incubation of soluble full-length OSM in MCF-7 breast
carcinoma cell CM resulted in two major OSM species of MWs 24 kDa and 22 kDa observed by immunoblot analysis
(Fig. 7A). These OSM species were not apparent after incubation of OSM in control SFM (Fig. 7A). In contrast to the
proteolysis of soluble full-length 26 kDa OSM by MCF-7 CM, OSM bound to collagen type XI was protected from
proteolysis (Fig. 7B), and the 26 kDa OSM protein remained intact over time. The protein-processing site in 26 kDa
OSM is localized to the C-terminal tail, and binding of full-length OSM to substratum was demonstrated to inhibit the
proteolytic processing. This observation provided further evidence that 26 kDa OSM binds to ECM via its C-terminal
tail.
MCF-7 breast carcinoma cell CM was utilized because it was found to efficiently process all of the 26 kDa OSM into
lower MW species. T47D CM was also observed to process soluble OSM, although the processing of the 26 kDa fulllength OSM was less extensive (Fig. 7C). CM from OSM-treated T47D cells, though, was associated with the
induction of an extracellular protease activity that was able to generate the 24 kDa OSM species (Fig 7C), which was
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observed to be constitutively expressed in MCF-7 CM (control in Fig 7A). This experiment demonstrated that the
processing of full-length OSM by cell-line specific proteases resulted in different MW OSM species, which were
previously observed to be associated with different adhesive properties (Fig. 2).
In an inflammatory environment, OSM may be in an acidic pH for prolonged periods of time. OSM has a basic
isoelectric point of 9.97 to 10.71, which is the pH at which it has no net charge. To evaluate its stability at a pH
associated with inflammation, OSM was immobilized and incubated at pH 5.5, 6.5 and 7.5 for eight days (37 ºC).
T47D cells were then added, and pSTAT3 was assessed after 2 hours. Immobilized OSM was observed to induce
pSTAT3 in T47D cells following an extended incubation for eight days at pH 5.5, 6.5, and 7.5. This experiment
indicated that OSM bound to ECM was able to maintain a bioactive conformation in an acidic environment many pH
units from its theoretical pI.
4. Discussion
Several studies have indicated a role for OSM in regulating pathological processes associated with chronic
inflammation including cancer (11), arthritis (16, 17, 19, 20), Alzheimer’s disease (21-23), and atherosclerosis (24).
Inflammation contributes to almost all aspects of tumor progression and is also a consequence of tumor development
(62). Cancer-associated inflammation is a key determinant in tumor progression and has been cited as the seventh
hallmark of cancer (27, 32, 62-64). Epidemiological data indicate that over 25% of all cancers are related to chronic
infections and other types of chronic inflammation (25). Chronic inflammation may not initiate tumor growth but
rather, enhances tumor progression and metastasis by providing a nurturing and pro-tumorigenic microenvironment
(65, 66).
OSM is localized to and secreted from tumor cells, lymphocytes (67), macrophages (11, 68), and neutrophils (6, 17,
56). We have previously reported that breast cancer cells induce the secretion of OSM from neutrophils (6). In
addition, OSM is reported to be chemotactic for neutrophils (11, 69) and macrophages (70). Each step of tumor
progression from initiation through metastasis is promoted via communication between tumor and
inflammatory/immune cells through the secretion of cytokines, chemokines, growth factors and proteases that remodel
the tumor microenvironment (65-71). It should be noted that ECM proteins play a key role at sites of inflammation
where they regulate the inflammatory properties of infiltrating leukocytes (72).
In the current study, evidence is provided employing a co-culture model and immunohistochemical analysis of human
tumor tissue suggesting that neutrophils may be an important source of OSM that ultimately ends up immobilized to
ECM. This immobilized OSM may function to shape and control a particular microenvironment over an extended
period of time into one that is inflammatory and pro-tumorigenic. OSM was also demonstrated to bind in a bioactive
conformation to the ECM components collagens I and XI, fibronectin, and laminin, as well as other substratum
including plastic. Many proteins and cytokines are sequestered in the ECM, but most such as TGFEand HGF are
bound in a biologically inactive state that requires proteolytic processing to generate a bioactive protein (73-76).
Full-length OSM (227 amino acids), 24 kDa OSM (209 amino acids), and truncated 22 kDa OSM (196 amino acids)
were observed to bind to the ECM proteins collagen type I, collagen type XI, laminin, and fibronectin in a pHdependent fashion, with the greatest overall binding observed at acidic pH. In general, 24 kDa OSM bound to
substratum more readily than full-length, or truncated 22 kDa OSM at all pH values examined. Surprisingly, 45 kDa
glycosylated OSM bound very weakly to ECM (Sup. Fig. 2C), suggesting a mechanism by which the N-linked glycans
sterically hindered the accessibility of ECM binding sites. OSM is glycosylated at two sites, N-106 and N-192, with
the latter residue localized to the C-terminal region of OSM that is involved in binding to ECM. The pH-dependent
binding of OSM to ECM proteins suggested electrostatic bonds mediated by charged residues in OSM and the ECM
proteins.
An OSM derived heparin-binding peptide consisting of the C-terminal amino acids C202--G223) has been reported
to bind to fibromodulin and osteoadherin via basic amino acid pairs, or doublets (51). Differences in the distribution
of basic amino acids, or doublets in the ECM binding domains of proteins including OSM, as well as the distribution
of sulfates in the tyrosine sulfate-binding domains of ECM proteins are reported to influence the binding of these
proteins to ECM (51). A higher ‘state of charge’ (charge density) in the sulfates associated with tyrosine sulfate- rich
domains of ECM proteins also enhances binding to heparin-binding protein motifs, including the OSM peptide
described above (51). In a previous study we established that collagen type XI contains multiple proteoglycan binding
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sites that include four lysine residues K-147, K-148, K-149 and K-152 (77). Replacement of K-148, K-149 and K-152
decreased binding to heparin sulfate, whereas replacement of K-147 increased binding 5-fold (77). In addition, an
essential role for ionic interactions in the binding of fibronectin to collagen has also been reported that involves lysine
and arginine residues (78). These studies indicate the similar nature of OSM and ECM electrostatic binding sites and
also illustrate the importance of position and composition of particular charged amino acids or amino acid pairs in
regulating electrostatic binding interactions.
The pH-dependent binding of OSM to ECM indicated electrostatic interaction and the likely involvement of amino
acid side chains that undergo changes in protonation state between pH 5.5 and 7.5 in OSM and/or the ECM molecules.
Arginines exist in a protonated state at the pH values used in these studies, and histidine with a pK a of 6.0 will
experience changes in its protonation state at pH 5.5 compared to pH 7.5. OSM is a very basic protein with an
isoelectric point of 9.97-10.71. With a pI of 9.97-10.71, OSM will be in a highly charged, protonated state between
pH 5.5 and 7.5, which are the pH utilized in this study. The high pI of OSM and its ‘state of charge’ at the pH examined
(5.5-7.5) could explain why OSM readily binds to many different ECM proteins, as well as plastic. In the current
study, IL-6 with a pI of 5.3-7.0 did not bind to collagens type I and XI, whereas LIF with a pI of 8.9-9.6 was observed
to bind, although not to the extent that OSM bound. The ‘state of charge’ of these OSM related cytokines at pH 7.5
paralleled their ability to bind to collagens type I and XI.
The qualitative differences observed between the binding of 22 kDa, 24 kDa, and 26 kDa OSM to ECM may result
from the particular complement of charged amino acids associated with the different OSM C-terminal tails. IL-6
contains seven charged amino acids but no doublets of basic amino acids in its C-terminus, and it did not bind to
collagens type I and XI. LIF contains a cluster of three consecutive lysines in its C-terminus and it did bind to
collagens type I and XI, but not as well as OSM. The thirty-one amino acid C-terminal extension of 26 kDa OSM
contains thirteen charged amino acids including five pairs of basic amino acids, versus six charged residues associated
with the C-terminus of 22 kDa OSM, which contains only one pair of arginine residues. This suggests that the greater
number of charged amino acids, or pairs of basic amino acids associated with the C-terminal extension of full-length
OSM compared to 22 kDa OSM enhanced its ability to bind to ECM at pH 6.5 and pH7.5. At pH 5.5, though, similar
levels of 22 kDa and 26 kDa OSM bound to ECM indicating binding sites not associated with the C-terminal extension,
such as the cluster of three arginines associated with the 22 kDa OSM C-terminus, or alternatively, differences in the
‘state of charge’ and reactivity of sulfates associated with tyrosine sulfate rich binding domains of ECM proteins.
Compared to 22 kDa OSM, the 24 kDa OSM C-terminal tail contains an additional thirteen amino acids that includes
six basic residues. These include two histidines, in addition to two basic amino acid doublets in the last six amino
acids of the 24 kDa C-terminus (197-HSPHQALRKGVRR-209). The greater overall binding of 24 kDa OSM to ECM
proteins indicated the importance of this particular complement of basic amino acids in OSM immobilization. The
observation that 24 kDa OSM bound to ECM more readily than 26 kDa OSM suggested that the composition or
position of basic amino acids in the 24 kDa C-terminus may be associated with a more flexible conformation and have
easier access to ECM binding sites, or bind to ECM sites with a higher affinity. If particular basic amino acids, or
doublets associated with the C-terminal extension of 26 kDa OSM are the first to come into contact with, and bind to
the primary ECM binding site then this would prevent the association of basic amino acids of the 24 kDa and 22 kDa
C-terminal binding domains within 26 kDa OSM with the same ECM binding site. The 26 kDa OSM C-terminal
extension contains a lysine-arginine, as well as an arginine-lysine pair of amino acids that may readily bind to ECM
but with a lower affinity than the arginine-arginine doublet, or histidines associated with the cluster of basic amino
acids in the 24 kDa OSM C-terminal extension. Low affinity binding sites may result in the loss of OSM during the
extensive washes that follow the binding incubation.
Peptides derived from various heparin-binding protein motifs, including the C202--G223 amino acid binding domain
of OSM, which contain different patterns of basic amino acids are associated with different heparin binding affinities
(51). A peptide with two arginine-arginine doublets has a different binding affinity than a peptide with a lysine-lysine
doublet and a lysine-arginine doublet. The peptide derived from OSM that is associated with an arginine-arginine
doublet, as well as two arginine-lysine doublets and a lysine-arginine doublet had the highest heparin binding affinity
(51). The different positions of basic amino acids in the peptides, as well as the positions and ‘state of charge’ of
sulfates in the tyrosine sulfate binding domains of ECM proteins are also associated with differences in binding
affinities (51). It is important to note that the binding experiments in the current study were carried out in SFM, which
contains physiological salt concentrations. These ions will also interact with charged amino acid residues in OSM and
the ECM and affect their conformation and accessibility to potential binding sites, as well as binding affinities.
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It was uncertain whether electrostatic bonds that immobilize OSM to ECM remain stable over the course of a
prolonged period of incubation, thus we examined the potential role of disulfide bonds in OSM immobilization. OSM
contains five cysteine residues, with three localized to its surface (60). The intramolecular disulfide bridge at C49C167 is crucial for OSM activity (60), which would prevent the immobilization of bioactive OSM. However, the free
cysteine residue C80 and the C6-C127 intramolecular disulfide bridge of human OSM are not required for OSM
activity, are localized to the molecular surface of OSM, and are suggested to mediate the covalent binding of OSM to
gold nanoclusters (52).
In the current study, the disulfide reducing agent DTT was observed to inhibit or reduce the levels of 24 and 26 kDa
OSM binding to ECM with a greater inhibitory effect on full-length 26 kDa OSM binding. It is interesting to note that
the presence of a disulfide bond in a protein is reported to regulate its ‘z number’, which is the number of charged
amino acid residues that are able to interact with a particular surface (79). This observation suggests a mechanistic
link between the presence of a disulfide bond in a protein such as OSM and its ability to electrostatically bind to ECM
via charged amino acid residues. OSM, as well as the ECM proteins examined in this study contain disulfide bonds,
which may include intra-, as well as inter-molecular bonds that regulate and maintain the conformations of these
proteins (80). In our study, DTT was observed to reduce the binding of OSM to four different ECM proteins, which
supported an effect on OSM conformation rather than on the ECM proteins. It is difficult to distinguish the effects of
DTT from the electrostatic binding of OSM to ECM. Future studies will investigate the contribution of specific
sulfhydryl groups (cysteines 6, 80, and 127) on OSM binding to ECM by site-directed mutagenesis to generate OSM
cysteine mutants, however these studies are beyond the scope of this paper.
STAT3 signaling in an inflammatory microenvironment is a major factor in determining whether an elicited immune
response is tumor promoting or inhibitory (66). In addition, the STAT3 signaling pathway is an important factor in
the regulation of cancer-associated inflammation (31-36, 81, 82). STAT3 signaling shapes and controls a particular
microenvironment into a pro-tumorigenic inflammatory microenvironment (31, 34, 82) and is constitutively activated
at sites of chronic inflammation (36, 83-85). Furthermore, sustained STAT3 signaling in tumor cells has been shown
to enhance proliferation, survival, angiogenesis, invasion, and tumor-promoting inflammation (32, 61). OSM
contributes to the chronic inflammation associated with the progression of atherosclerosis via STAT1 and STAT3
signaling (24), and OSM-expressing macrophages are observed in lesions from all the patients examined (24).
Unphosphorylated STAT3 has also been reported to mediate cell signaling (38, 86, 87) and to regulate and activate
cellular programs associated with inflammation (37, 38). In this study, we established that OSM immobilized to ECM
mediated a sustained and enhanced expression of pSTAT3, as well as STAT3 and STAT1 protein levels in breast
cancer cells. The induction of pSTAT3 in breast cancer cells by immobilized OSM was inhibited by an OSM
neutralizing antibody, which indicated that the OSM-ECM binding site was distinct from the OSM receptor binding
site. The enhanced expression of STAT1 and STAT3 suggests an important role for OSM in cancer-associated
inflammation and tumor progression. Future experiments will establish whether the increases in STAT1 and STAT3
protein levels result from an induction of expression, or an enhanced stability and increase in half-life.
The activity of OSM immobilized to ECM was also demonstrated by OSM-induced morphology changes in T47D
cells. These changes were observed using the ‘OSM circle’ assay, where OSM was immobilized in a small circle of
ECM and then incubated with T47D tumor cells for up to 28 days. Under these conditions, OSM induced EMT-like
morphological changes in tumor cells that included rounding-up and detachment from substratum. These changes
were observed almost exclusively in cells inside the OSM circle, while cells outside the circle maintained control
morphology. Cells inside the ‘OSM circle’ undergoing OSM induced morphological changes could also be
distinguished from control cells outside the ‘OSM circle’ by their light refraction/reflection properties under a phase
contrast microscope. Cells inside the ‘OSM circle’ appeared much brighter than cells outside the circle, which
maintained control morphology and were darker in intensity. Together, these experiments indicated that OSM
immobilized to ECM was bioactive and able to bind to cellular OSM receptors and that detachment from ECM was
not necessary to elicit an OSM response. The ability of OSM to remain localized in a particular microenvironment for
prolonged periods of time indicated that immobilized OSM may mediate the long-term behavior of cells that come
into contact with this cytokine, including an EMT in tumor cells. The binding of OSM to ECM in a bioactive
conformation is a novel observation and suggests that immobilized OSM may help shape a microenvironment into
one that is conducive to inflammation and metastasis.

11

This is an author-produced, peer-reviewed version of this article. The final, definitive version of this document can be found online at Cytokine,
published by Elsevier. Copyright restrictions may apply. doi: 10.1016/j.cyto.2014.11.007

An epithelial-mesenchymal transition is considered a hallmark of a metastatic tumor and involves changes in gene
expression that result in coordinated changes in cell morphology, which are associated with enhanced motility,
protease secretion, and the disruption of intra- and inter-cellular junctions (88-92). OSM is reported to mediate an
EMT in tumor cells via STAT3 signaling (2, 61, 93, 94). We previously described EMT-like morphological changes
induced in T47D cells by OSM that involved a disruption of intra- and inter-cellular junctions, enhanced invasion,
and secretion of extracellular proteases that culminated in cell detachment from substratum (3). These morphological
changes were reversible upon elimination of OSM, although single cells (but not multi-cell islands) induced to detach
by OSM generally became apoptotic unless OSM was removed. Recently, a number of EMT markers induced by
OSM in T47D and MCF-7 cells have been reported including snail and slug, as well as the CD44+/CD24- phenotype
(2, 7). IL-6 is also reported to induce morphological changes in T47D and ZR-75-1 breast cancer cells, as well as
detachment from substratum and enhanced motility that is associated with an EMT (95-98).
In the current study, we demonstrated that OSM immobilized to ECM was protected from proteolysis due to tumorassociated proteases and remained active after prolonged incubation at an acidic pH associated with an inflammatory
environment. This suggested that the stability of OSM was maintained by immobilization, which also likely increased
its half-life, although since OSM will bind to substratum during prolonged incubation it is difficult to establish a
soluble OSM control for comparison. Since the proteolytic processing site in full-length OSM is associated with the
C-terminal tail, the inhibition of OSM processing by immobilization to substratum provided further evidence that the
C-terminal OSM tail was involved in binding to ECM and was not accessible to proteases. In addition, we observed
that OSM induced the expression of a protein processing activity in T47D CM, constitutively expressed in MCF-7
CM that mediated the conversion of soluble full-length OSM into 24 kDa OSM. It is well established that proteases
are key mediators of metastasis as well as inflammation, and we have previously observed that OSM induces the
secretion of cathepsins D and L from breast cancer cells (3). The protection from proteolysis and the stability at acidic
pH for prolonged periods displayed by immobilized OSM represents another mode of OSM regulation by the ECM
and cell microenvironment. By binding to ECM, the biological effects of OSM may be prolonged by preventing its
proteolysis from proteases associated with tumors and an inflammatory environment, as well as by maintaining its
stability in different physicochemical environments. Surprisingly, very little in known regarding the MWs and
properties of OSM species associated with different pathological processes, including cancer, arthritis, and
Alzheimer’s disease. The processing of glycosylated or full-length OSM in a specific microenvironment that is
associated with a particular complement of extracellular proteases may generate different MW OSM species with
different biological properties such as adhesiveness.
The binding of OSM to ECM in a bioactive conformation may represent an early inflammatory event, which over
time may exert an influence over a particular microenvironment culminating in chronic inflammation or metastasis.
Chronic inflammation, in general, involves a temporal increase in the concentration of pro-inflammatory cytokines in
an environment that is also associated with a constant diffusion of cytokines out of the area. Immobilization of a proinflammatory cytokine in a discrete microenvironment will increase the local cytokine concentration and reduce the
amount of cytokine necessary to maintain inflammation. In addition, the immobilization of OSM to substratum may
serve to concentrate and restrict the activity of OSM to discrete microenvironments where it can maintain long-term
biological effects. The immobilization of OSM to ECM may also sequester OSM away from certain populations of
cells in a microenvironment. The pH dependency of OSM binding to ECM suggests a plausible role for pH in
regulating the state of OSM attachment to ECM occurring during the development and cessation of inflammation. As
inflammation develops in a microenvironment, the pH decreases and OSM will bind more readily to ECM; as
inflammation subsides, the pH will rise and OSM will detach and be cleared from the microenvironment.
Our model describing the role of immobilized OSM in the acquisition of chronic inflammation and metastasis is
depicted in Figure 8, where infiltrating inflammatory cells (or tumor cell subpopulations) secrete OSM. The
inflammatory or tumor cells expressing OSM receptors may then interact with the immobilized OSM to initiate
signaling (Fig. 8, upper panel). OSM is reported to be chemotactic for neutrophils and macrophages (11, 69, 70), and
the slow release of OSM from ECM may enhance the infiltration of additional inflammatory cells (Fig. 8, lower panel).
Infiltrating inflammatory cells, migrating tumor cells, or cancer cells at the invasive edge of a tumor may come into
contact with the immobilized OSM and initiate another round of inflammatory events resulting in chronic
inflammation or an EMT and metastasis in tumor cells.
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In conclusion, the binding of OSM to ECM represents the first of several inflammatory events in a particular
microenvironment that may result in chronic inflammation, if inflammatory cells are involved, or tumor metastasis
and tumor associated-inflammation, if tumor cells interact with the immobilized OSM. OSM bound to ECM proteins
via electrostatic bonds associated with basic amino acids in the OSM C-terminus. Immobilized OSM was bioactive
and induced a sustained expression of pSTAT3, as well as STAT3 and STAT1 protein in T47D and ZR-75-1 breast
tumor cells. The OSM ‘circle assay’ demonstrated that immobilized OSM remained localized in a discrete
microenvironment where it mediated prolonged biological effects in tumor cells. Immobilized OSM was also observed
to be resistant to proteolysis from tumor-associated proteases, and OSM was observed to induce an extracellular
protease activity in T47D cells capable of processing soluble full-length OSM. Lastly, the data in this study provided
further evidence for the role of inflammatory processes in cancer.
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Figure Legends
Figure 1. In vitro and in vivo evidence that OSM binds to ECM. (A)
OSM-expressing neutrophils were co-cultured with MDA-MB-231 breast cancer cells (10:1 ratio neutrophils to tumor
cells), and no association of OSM with tumor cell ECM was apparent at 24 h. (B) Following 48 h incubation with
neutrophils, OSM immobilized to the ECM of tumor cells was observed (arrow). (C-D) Low and high magnification
photomicrographs of OSM expressing neutrophils in a colorectal tumor section. The colon cancer cells were negative
for OSM expression, although a large population of OSM-expressing neutrophils that had infiltrated into the tumor
was apparent (C). Upon high magnification, OSM associated with tumor ECM was observed (D; arrow). (E-F) OSM
associated with the ECM of serial sections of an ovarian tumor. The similar patterns of OSM localized to the ECM of
serial sections provided evidence against artifactual staining. (F) A circular orifice surrounded by OSM staining was
apparent (arrow), which may represent a neutrophil canal. (G) An ovarian tumor section, which contains a neutrophil
canal with OSM-expressing neutrophils.
Figure 2. OSM binds ECM proteins via electrostatic bonds: additional evidence for covalent disulfide bonds. (A)
Full-length 26 kDa OSM and mature 22 kDa OSM were bound to ECM in a 3 h incubation, 37o C in SFM at pH 5.5,
6.5 and 7.5. OSM was observed to bind to all ECM proteins in a pH-dependent fashion with greater 26 kDa OSM
binding observed at pH 6.5-7.5. (B) The binding of full-length OSM compared to 24 kDa OSM. 24 kDa OSM was
observed to bind to each ECM protein to a greater extent than 26 kDa OSM at pH 6.5-7.5, with more similar levels of
binding apparent at pH 5.5. (C) The binding of OSM to ECM in the presence or absence of DTT (1 mM) inhibited,
or partially inhibited the binding of OSM to each of the ECM proteins tested.
Figure 3. Binding kinetics assessed by surface plasmon resonance.
OSM was covalently coupled to the surface of a sensor chip and ECM proteins in solution were able to bind to the
OSM. (A, C, E) 22 kDa human OSM covalently coupled to sensor chip, (B, D, F) 26 kDa human OSM covalently
coupled to sensor chip. (A, B) Col11a1 fragment sample concentrations ranged from 11 pM to 123 nM. The
association and dissociation phases are shown as refractive index units versus time. (C, D) Fibronectin sample
concentrations ranged from 104 pM to 1μM. (E, F) Laminin sample concentrations ranged from 39 pM to 720 nM.
Arrow indicates time of transition from association to dissociation due to buffer change. The K D , K on and K off values
calculated from the global fitting of all concentrations are reported in Table 2.
Figure 4. OSM bound to ECM is biologically active.
STAT3 phosphorylation by OSM acting as a soluble ligand and as a solid-phase ligand immobilized to ECM was
examined. (A) Time course examining the phosphorylation of STAT3 by soluble 26 kDa and 22 kDa OSM. (B) OSM
immobilized to ECM proteins (2 h, 37ºC, pH 7.5) induced pSTAT3 in T47D cells following a 2h incubation that was
inhibited with a neutralizing antibody to OSM. (C) OSM immobilized to ECM (2 h, 37ºC, pH 7.5) induced pSTAT3
in ZR-75-1 cells following a 24h incubation that was inhibited by a neutralizing antibody to OSM.
Figure 5. Immobilized OSM induces and maintains elevated levels of pSTAT3 and enhances the expression of
STAT3 and STAT1 in breast cancer cells. (A)
Full-length OSM was immobilized to collagen type XI overnight (37ºC, pH 7.5). T47D cells were added and incubated
for 5 days. Immobilized OSM induced and sustained elevated levels of pSTAT3 and STAT3. (B) OSM immobilized
to collagen type I induced the expression of STAT1 in T47D cells. Following overnight immobilization of OSM to
collagen type I (37ºC, pH 7.5), T47D cells were added and incubated for 4 days. (C) Protein array analysis indicated
that soluble OSM also induced the expression of STAT3 and STAT1 in ZR-75-1 cells. OSM-treated and control ZR75-1 cells were subjected to a BD Powerblot protein array analysis. ZR-75-1 cells treated with soluble OSM for 2
days were associated with a 2-fold increase in the expression levels of both STAT1 and STAT3 compared to controls.
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Figure 6. OSM immobilized to ECM induces morphological changes in T47D cells over prolonged incubation
periods. (A)
Using the ‘OSM circle’ assay, OSM (50 ng: 100 μg/ml stock) was spotted onto laminin and incubated for 3 h (pH
7.5), followed by incubation of the immobilized OSM for 5 days. After washes, T47D cells were added and incubated
for 8 days. Following eight days incubation, cells inside the OSM circle (B; 40X and D; 100X) were rounded-up and
almost completely detached compared to cells outside the circle that maintained a control morphology (C; 40X and
E; 100X). (F-I) T47D cells were also cultured for 28 days with full-length OSM immobilized to plastic. Phasecontrast microscopy was employed to assess the morphology changes and light reflecting/refracting properties of cells
associated inside the ‘OSM circle’ compared to cells outside the circle. After 28 days, differences in morphology and
the light scattering properties of tumor cells inside the OSM circle were clearly evident (F; 40X and H; 100X) when
compared to cells outside the circle (G; 40X and I; 100X), which also indicated differences in cell number.
Figure 7. Immobilized OSM is protected from proteolysis and maintains activity following prolonged incubation at
acidic pH.
Conditioned medium from MCF-7 breast carcinoma cells (collected after 24h from confluent cells) was incubated
with (A) soluble OSM and (B) OSM bound to collagen type XI. Extracellular proteases associated with MCF-7 cells
were able to cleave soluble full-length OSM into 24 kDa and 22 kDa OSM species (A). Immobilized OSM was
resistant to proteolytic processing form tumor CM associated proteases (B). (C) OSM treatment of T47D cells (left
side) induced an extracellular protease activity, constitutively expressed in MCF-7 conditioned medium (right side)
that generated 24 kDa OSM. (D) OSM bound to ECM and incubated at pH 5.5-7.5 for 8 days retained the ability to
induce pSTAT3 in T47D cells following a 2 h incubation.
Figure 8. Model for OSM role in chronic inflammation and tumor metastasis. (A)
Inflammatory cells infiltrate into a particular microenvironment and secrete OSM, which binds to ECM and helps to
nurture an inflammatory or pro-metastatic microenvironment. (B) Immobilized bioactive OSM maintains a prolonged
OSM response ultimately resulting in chronic inflammation or tumor metastasis. A non-OSM secreting, proliferating
tumor may also come into contact with immobilized OSM secreted from inflammatory cells. The interaction of
immobilized OSM with proliferating tumor cells may induce an EMT in the tumor cells and enhance tumor metastasis.
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Appendix A. Supplemental Data
Supplemental Figure 1. OSM protein band intensities assessed by immunoblot analysis do not parallel associated
pSTAT3 band intensities: differences in the thresholds of detection for OSM binding versus OSM activity assays.
Fifty nanograms of 22 kDa and 26 kDa OSM were immobilized to collagen type XI or plastic for 24 h, 37ºC, pH 7.5.
Unbound cytokine was eliminated with extensive washes, and the samples were then incubated overnight in SFM.
After two additional washes, T47D cells were added and incubated for 24 h. Immobilized OSM protein bands, as well
as the pSTAT3 levels that corresponded with each OSM band, were examined via immunoblot to compare the
intensities of the OSM versus pSTAT3 protein bands. No 22 kDa OSM band was associated with binding to collagen
type XI, whereas a heavy 22 kDa OSM band was associated with binding to plastic. Each of these OSM species was
associated with a roughly similar pSTAT3 band. A faint intensity 26 kDa OSM band was associated with binding to
plastic compared to a strong 26 kDa band associated with binding to collagen type XI. Each of these OSM bands was
associated with pSTAT3 bands of comparable intensity. Lastly, no 22 kDa OSM binding to collagen type XI was
apparent binding, whereas a strong 26 kDa OSM band was observed. The pSTAT3 band associated with 26 kDa OSM
was of greater intensity than that observed for 22 kDa OSM, although the levels of pSTAT3 expression between 22
kDa and 26 kDa OSM were much more similar than the levels of 22 kDa versus 26 kDa OSM protein binding.
Supplemental Figure 2. pSTAT3 induction employed to compare the binding of OSM, IL-6 and LIF to collagen
types I and XI. (A) and (C)
Cytokines (50 ng) were incubated overnight with collagen types I and XI coated culture wells (complete RPMI, pH
7.5). T47D cells were added and harvested after 3 and 24 hrs to assess immobilized cytokine bioactivity via pSTAT3.
The 3-hour time-point was chosen because this was the earliest time at which cells flattened-out to control
morphology. Twenty-four hrs was chosen since this was a time-point at which immobilized OSM induced pSTAT3
reached a maximum (Fig 4). 26 kDa OSM, and 22 kDa OSM bound strongly; LIF bound weakly and IL-6 and
glycosylated OSM (G-OSM) did not bind as assessed by the intensity of pSTAT3 bands (A) and (C). (B) and (D)
Cytokine that did not bind to collagen types I and XI following 24 h incubation (from A and C) was collected and
applied to T47D cells and examined for pSTAT3 expression at 30 min and 24 hrs. Thirty minutes and 24 hrs were
chosen since these time-points were associated with maximum levels of pSTAT3 expression (Fig. 4). The ability of
unbound cytokine from (A) and (C) to induce pSTAT3 expression when reapplied to T47D cells demonstrated that
the cytokines employed in the experiment were active and were present in sufficient quantity to saturate the collagen
type I and XI binding sites. The weak pSTAT3 band observed for unbound LIF, though, compared to OSM and IL-6
suggested that LIF may have bound to collagen types I (A) and XI (C) in an inactive conformation resulting in a loss
of active LIF (B) and (D). A lower number of LIF/OSM receptors compared to OSM and IL-6 receptors in T-47D
cells may also explain the low intensity pSTAT3 band generated by LIF. In contrast, unbound OSM and IL-6 reapplied to T-47D cells was observed to generate similar heavy intensity pSTAT3 bands, which suggested that these
cytokines were not immobilized to collagen types I and XI in an inactive conformation. (E) Glycosylated OSM was
observed to bind to collagen type I when the binding assay was conducted with SFM. The binding experiments
depicted in (A) and (C), employed complete RPMI (10 % FBS) and no G-OSM binding was observed.
Supplemental Figure 3. OSM immobilized to ECM induces morphological changes in T47D cells over prolonged
incubation periods: OSM effects are confined to the ‘OSM circle’ indicating that immobilized OSM is able to bind to
cellular OSM receptors.
Full-length OSM (50 ng: 100 μg/ml stock) was spotted onto poly-D-lysine (A-D) and incubated for 3 hrs (37ºC, pH
7.5). After extensive washing, the immobilized OSM was incubated for 5 days without tumor cells in complete RPMI.
After washing, T47D cells were added and cultured for 8 days. Phase-contrast microscopy was then employed to
assess the morphology changes and light reflecting/refracting properties of cells associated with the OSM circle
compared to cells outside the circle. (A) Following incubation for 8 days, T47D cells (40X) within the OSM circle
were much brighter than cells outside the circle, which resulted from differences in light reflection/refraction of cells
undergoing morphology changes associated with an EMT. Most cells within the OSM circle detached, resulting in far
fewer cells inside the circle. (B) T47D cells (40X) outside the OSM circle maintained a control-morphology and
approached confluence. (C) T47D cells (100X) inside the circle were ‘rounded-up’ and detaching with different light
scattering properties (bright cells) than (D) cells (100X) outside the circle, which maintained a control polygonal
morphology and appeared darker under a phase contrast microscope. (E-H) A prolonged twenty-eight day incubation
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of T47D cells with 22 kDa OSM immobilized to plastic was also examined. (E) (25X) (F) (40X) After 28 days,
differences in the light scattering properties of T47D tumor cells inside the OSM circle were clearly evident when
compared to cells outside the circle. (F) Morphological changes induced by OSM were apparent in cells inside the
circle, versus those outside the circle (40X). Tumor cells just outside the border of the OSM circle maintained a
control-morphology, indicating that OSM remained immobilized and confined to the circle. (G) Cells (100X) inside
and (H) outside the OSM circle demonstrated differences in morphology and cell number.
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